



68° CONGRESSO NAZIONALE SIGG

Ritorno al futuro

FIRENZE, 13-16 DICEMBRE 2023  
PALAZZO DEI CONGRESSI





# Strategie anti-aging attraverso farmaci senolitici e approccio di restrizioni dietetica


Dott. Luca Tagliafico

Corso di Dottorato in Emato-oncologia e Medicina Interna Clinico-traslazionale

Curriculum di Gerontologia, Fisiopatologia delle Malattie Geriatriche e Medicina Anti-aging


















Condition	Senolytic agent used	Age	Summary of immune cell-related outcome measures <sup>a,b</sup>	Study phase	Estimated study start & completion date	NCT number
Osteoarthritis	Fisetin	40–85	Senescent PBMC quantification using flow cytometry	Phase 1 Phase 2	May 2021– June 2025	<a href="#">NCT04815902</a>
Interstitial lung disease in COVID	Fisetin	18+	Immunophenotyping to examine changes in peripheral T cells	Phase 2	Mar 2023– December 2024	<a href="#">NCT05593588</a>
Frailty in survivors of childhood cancer	Fisetin Dasatinib & Quercetin	18+	p16INK4a mRNA expression in CD3 <sup>+</sup> cells	Phase 2	June 2022– July 2024	<a href="#">NCT04733534</a>
Alzheimer's disease	Dasatinib & Quercetin	65+	Measurement of senescent CD3 <sup>+</sup> cells expressing p16	Phase 1 Phase 2	May 2022– June 2023	<a href="#">NCT05422885</a> (STAMINA)
Alzheimer's disease	Dasatinib & Quercetin	65+	Measurement of senescent CD3 <sup>+</sup> cells expressing p16	Phase 2	Dec 2021– January 2023	<a href="#">NCT04685590</a> (SToMP-AD)
Recent HIV infection	Dasatinib monotherapy	18–65	Phenotyping of senescence markers in PBLs (Beta-galactosidase, Bcl-2, Histone H2A, p16 and CD87)	Phase 2	Nov 2022– December 2024	<a href="#">NCT05527418</a> (DASAHiVCURE)


































**Clinical study timeline for 12 monthly FMD cycles in patients with aMCI or mild AD:**





Totale pazienti: 40 (di cui 20 nel gruppo di trattamento e 20 in quello di controllo)

Età:

Controllo: mediana 74 IQR 70-75

Trattamento: mediana 72 IQR 69-76

Sesso:

Controllo: 11F 9M

Trattamento: 14F 6M

Compliance: sovrapponibile fra i due gruppi

10 hanno completato il ciclo nel gruppo di controllo

11 hanno completato il ciclo nel gruppo di trattamento



# 68° CONGRESSO NAZIONALE SIGG


Ritorno al futuro


FIRENZE, 13-16 DICEMBRE 2023  
PALAZZO DEI CONGRESSI



	t6 vs t0	t12 vs t0
deltaFFM%	W = 80.5, p-value = 0.91	W = 52, p-value = 0.86
deltaFM%	W = 75.5, p-value = 0.91	W = 58, p-value = 0.86
deltaTBW%	W = 87, p-value = 0.64	W = 40, p-value = 0.31
deltaWeight%	W = 109, p-value = 0.21	W = 74, p-value = 0.19
deltaPhAngle%	W = 97.5, p-value = 0.30	W = 70, p-value = 0.31
deltaACE-R	W = 79.5, p-value = 0.59	W = 91, p-value = 0.28
deltaADL	W = 92, p-value = 0.97	W = 84.5, p-value = 0.29
deltaIADL	W = 103, p-value = 0.44	W = 56, p-value = 0.28
deltaBabcock-total	W = 117.5, p-value = 0.21	W = 88, p-value = 0.37
deltaCDR	W = 97.5, p-value = 0.59	W = 45, p-value = 1
deltaCES-D	W = 123.5, p-value = 0.12	W = 83.5, p-value = 0.52
deltaQoL-AD	W = 95.5, p-value = 0.59	W = 54, p-value = 0.48
deltaRockwood	W = 135.5, p-value = 0.03	W = 105, p-value = 0.06










**Endpoint primario: Valutare la fattibilità e la sicurezza della FMD in soggetti anziani pre-fragili di età compresa tra 60 e 80 anni**





Alessio Nencioni, MD  
Fiammetta Monacelli, MD PhD  
Irene Caffa, PhD

### *Postdocs*

Amr Khalifa, PhD  
Ana Guijarro, PhD  
Erica Parisi, PhD  
Moustafa Ghanem, PhD  
Tommaso Bonfiglio, PhD

### *PhD Students*

Angelica Persia  
Asmaa Neamatallah  
Consuelo Borgarelli  
Loredana Collura  
Luca Tagliafico, MD  
Mariya Muzyka, MD  
  
Silvia Buonopane  
Silvia Ottaviani, MD

## Laboratorio di Biogerontologia



# Università di Genova

### **Ringraziamenti:**

Patrizia Mecocci, MD PhD  
Virginia Boccardi, MD PhD  
Martina Pigliautile, PhD

